Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to Ustekinumab Due to Paradoxical Psoriasis,
Not applicable · Testing switch of anti TNF for ustekinumab for paradoxical psoriasis. · 1 site · Centre Hospitalier Universitaire de Nice
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
This study is testing switch of anti TNF for ustekinumab for paradoxical psoriasis. (a drug). Condition(s) listed: Chronic Inflammatory Bowel Diseases.
It is open-label: participants know what they are receiving.
This study does not use drug-development phases (it may test a device, diet, procedure, app, or care approach).
Who can join
- Ages 6 to 17
- Any sex
Some of the main requirements, copied from the record:
- Patients capable of giving their non-opposition
- Patient <19 years
- Diagnosis of IBD established
Plus 3 more requirement(s). There are also 3 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 40 participants are expected to take part.
- Start date: 2026-04-20.
- Main results expected around 2027-10-01 (estimate from the record).
- 1 study site listed (1 marked recruiting) in France.
Main thing being measured
- Proportion of patients maintaining UC or CD control between anti-TNF-α discontinuation (M0) and 3-6 months of ustekinumab treatment (M3-M6) (at baseline Month 0)
In the researchers’ words
Inflammatory bowel diseases (IBD) include Crohn's disease (CD) and ulcerative colitis (UC). They cause abdominal pain and chronic diarrhea and/or rectal bleeding, which can lead to weight loss and malnutrition.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Not applicable |
| Study type | Interventional |
| Conditions | Chronic Inflammatory Bowel Diseases |
| Lead sponsor | Centre Hospitalier Universitaire de Nice |
| Enrollment | 40 (estimated) |
| Start date | 2026-04-20 |
| Primary completion (est.) | 2027-10-01 |
| First posted | 2026-04-14 |
| Last updated | 2026-06-25 |
| Official title | Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Was Switched to Ustekinumab Due to Paradoxical Psoriasis: Real Life Data |
| ClinicalTrials.gov ID | NCT07529236 |
Interventions
- switch of anti TNF for ustekinumab for paradoxical psoriasis. (Drug)
After traitement 6 months of ustekinumab the patients are inclued in the study and the Medical file are used to complete the CRF. no specific intervention in the study
Full eligibility criteria (from the record)
Inclusion Criteria: 1. Patients capable of giving their non-opposition 2. Patient <19 years 3. Diagnosis of IBD established 4. Having received an anti-TNFα for IBD for at least 3 months 5. Having stopped the anti-TNFα for a severe paradoxical psoriasis resistant to usual treatments (topical or systemic) diagnosed by a dermatologist 6. Having received Ustekinumab in relay of the anti-TNFα Exclusion Criteria: 1. Patient > 18 years 2. Diagnosis of IBD not confirmed 3. Discontinuation of anti-TNFα for a cause other than psoriasis
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Nice | Nice, France | France | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.